Bavarian Nordic A/S

164 articles with Bavarian Nordic A/S

• Bavarian Nordic Announces Presentation Of Preliminary Phase 1 Results For The Ebola Prime-Boost Vaccine Regimen Of MVA-BN Filo And Janssen Pharmaceutical's AdVac Technology

  5/13/2015

• Bavarian Nordic Announces Positive Results From Two Pivotal Clinical Studies Of IMVAMUNE Smallpox Vaccine

  5/13/2015

• Bristol-Myers Squibb Bets $975 Million on Bavarian Nordic's Prostate Cancer Vaccine

  3/5/2015

• Bavarian Nordic Announces Updated Overall Survival Data From Combination Immunotherapy Data Of PROSTVAC Plus Ipilimumab At The 2015 Genitourinary Cancers Symposium

  2/24/2015

• Bavarian Nordic Announces Initiation Of Phase 1 Clinical Trial For The Ebola Vaccine Regimen Of MVA-BN® Filo And Janssen's AdVac® technology

  1/6/2015

• Bavarian Nordic Reaches Enrollment Target In The Pivotal Phase 3 Study Of PROSTVAC® In Prostate Cancer

  12/10/2014

• Ebola Clinical Trials: Big Name Players In The Ebola Race

  10/28/2014

• Johnson & Johnson Jumps Into The Ebola Race With Collaboration Of Crucell And Bavarian Nordic; Human Trials To Start In Early 2015

  9/4/2014

• Bavarian Nordic Accelerates Ebola Vaccine Development Programs In Collaboration With The NIH

  9/4/2014

• Bavarian Nordic Announces First Half 2014 Results

  8/28/2014

• Bavarian Nordic Receives Order From The Canadian Government To Supply IMVAMUNE® Smallpox Vaccine

  8/26/2014

• Bavarian Nordic Is The Sole Bidder For Canadian Smallpox Vaccine Supply

  8/6/2014

• Bavarian Nordic Announces First Patient Treated In A Phase 1 Study Of MVA-BN® Brachyury In Advanced Cancer

  7/24/2014

• Total Number Of Voting Rights And Share Capital In Bavarian Nordic

  6/2/2014

• Report Of Transactions Of Shares And Related Securities Of Bavarian Nordic By Persons Holding Managerial Responsibilities And/Or Persons/Companies Closely Associated With Such

  5/29/2014

• Bavarian Nordic Taps Paul Chaplin, Ph.D. For President & CEO Post

  5/29/2014

• Bavarian Nordic Issues New Shares In Connection With Exercise Of Warrants

  5/27/2014

• Bavarian Nordic Announces First Patient Treated In A Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 In Bladder Cancer

  4/28/2014

• Bavarian Nordic Welcomes Gerard Van Odijk As New Chairman Of The Board

  4/25/2014

• Bavarian Nordic - Report On The Results Of The Annual General Meeting, Held 24 April 2014

  4/25/2014